Dr. John J. Baldwin received his BS degree in Chemistry in 1956 from the University of Delaware and his Ph.D. Degree at the University of Minnesota. While at Minnesota, he was elected President of Sigma Xi and was recipient of the Outstanding Achievement Award in Organic Chemistry. After graduation, Dr. Baldwin spent over 40 years focused on drug discovery and in exploring new technologies to increase the efficiency of the discovery process. He started his career at the Merck Research Laboratories, leaving after 30 years with several drugs to his credit including Trusopt® and Cosopt®, both for the treatment of glaucoma. While at Merck he made important contributions to a wide range of therapeutic areas including, cardiovascular medicine with Aggrastat®, Aids with Crixivan®, and to peptic ulcer disease where he played a key role in the development of Pepcid®. Dr. Baldwin next became founder and Chief Scientific Officer of Pharmacopeia, a company specializing in new drug discovery technologies. From this work several drugs are currently undergoing clinical investigation. After 10 years at Pharmacopeia, he founded, and is President and Chief Scientific Officer for Vitae Pharmaceuticals where he applies computational and molecular simulation methods to the discovery of new therapeutic agents. Dr. Baldwin has published over 100 scientific articles and numerous reviews and has been an invited lector at more than 125 national and international symposiums. He holds over 180 issued United States patents. He has received several awards in recognition of his work including the prestigious Hershberg Award for Important Discoveries in Medically Active Substance and the Outstanding Achievement Award by the University of Minnesota. He was inducted into the Medicinal Chemistry Division Hall of Fame at the 2007 Fall ACS Meeting. He is a cofounder and member of the Board of Directors of WuXi PharmaTech in Shanghai, China; he also serves on the Board of Directors of GlycoMimetics and Glyconix Corporations.